Moreover, these findings have taken on clinical importance as the GLP-1R has been effectively targeted to lower glucose in T2D, either alone or when coupled with agents that also agonize the glucose-dependent insulinotropic polypeptide receptor (GIPR) (15). The gene discussed is GIPR; the disease is type 2 diabetes mellitus.